Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor-Reference-Cited by-同舟云学术

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Published:2018-01 Issue:3 Volume:172 Page:578-589.e17
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Janes Matthew R.,Zhang Jingchuan,Li Lian-Sheng,Hansen Rasmus,Peters Ulf,Guo Xin,Chen Yuching,Babbar Anjali,Firdaus Sarah J.,Darjania Levan,Feng Jun,Chen Jeffrey H.,Li Shuangwei,Li Shisheng,Long Yun O.,Thach Carol,Liu Yuan,Zarieh Ata,Ely Tess,Kucharski Jeff M.,Kessler Linda V.,Wu Tao,Yu Ke,Wang Yi,Yao Yvonne,Deng Xiaohu,Zarrinkar Patrick P.,Brehmer Dirk,Dhanak Dashyant,Lorenzi Matthew V.,Hu-Lowe Dana,Patricelli Matthew P.,Ren Pingda,Liu Yi

Funder

DOE Office of Science

Janssen Biotech

Wellspring Biosciences

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference56 articles.

1. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling;Athuluri-Divakar;Cell,2016

2. Genomic analyses identify molecular subtypes of pancreatic cancer;Bailey;Nature,2016

3. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1;Barbie;Nature,2009